Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSStandard

ZERBAXA

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

Standard Dose
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview ZERBAXA is listed in Drugs@FDA under application 206829 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM Form and strength POWDER;INTRAVENOUS - EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL Sponsor CUBIST PHARMS LLC Submission history Latest submission status date: 2022-04-21 00:00:00.

Structured Monograph

Clinical summary

Approval overview ZERBAXA is listed in Drugs@FDA under application 206829 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM Form and strength POWDER;INTRAVENOUS - EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL Sponsor CUBIST PHARMS LLC Submission history Latest submission status date: 2022-04-21 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.